Distinct Myeloid Suppressor Cell Subsets Correlate with Plasma IL-6 and IL-10 and Reduced Interferon-alpha Signaling in CD4⁺ T Cells from Patients with GI Malignancy
Overview
Oncology
Pharmacology
Authors
Affiliations
Interferon-alpha (IFN-α) promotes anti-tumor immunity through its actions on immune cells. We hypothesized that elevated percentages of myeloid-derived suppressor cells (MDSC) and increased pro-inflammatory cytokines in peripheral blood would be associated with impaired response to IFN-α in patients with gastrointestinal (GI) malignancies. This study evaluated relationships between plasma IL-6, IL-10, circulating MDSC subsets, and IFN-α-induced signal transduction in 40 patients with GI malignancies. Plasma IL-6 and IL-10 were significantly higher in patients versus normal donors. CD33(+)HLADR(-)CD11b(+)CD15(+) and CD33(+)HLADR(-/low)CD14(+) MDSC subsets were also elevated in patients versus normal donors (P < 0.0001). Plasma IL-6 was correlated with CD33(+)HLADR(-)CD15(+) MDSC (P = 0.008) and IL-10 with CD33(+)HLADR(-)CD15(-) MDSC (P = 0.002). The percentage of CD15(+) and CD15(-) but not CD14(+) MDSC subsets were inversely correlated with IFN-α-induced STAT1 phosphorylation in CD4(+) T cells, while co-culture with in vitro generated MDSC led to reduced IFN-α responsiveness in both PBMC and the CD4(+) subset of T cells from normal donors. Exploratory multivariable Cox proportional hazards models revealed that an increased percentage of the CD33(+)HLADR(-)CD15(-) MDSC subset was associated with reduced overall survival (P = 0.049), while an increased percentage of the CD33(+)HLADR(-/low)CD14(+) subset was associated with greater overall survival (P = 0.033). These data provide evidence for a unique relationship between specific cytokines, MDSC subsets, and IFN-α responsiveness in patients with GI malignancies.
Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation.
Ucgul E, Guven D, Ucgul A, Ozbay Y, Onur M, Akin S Cancer Control. 2024; 31:10732748241302248.
PMID: 39547932 PMC: 11569492. DOI: 10.1177/10732748241302248.
Calabro A, Drommi F, Sidoti Migliore G, Pezzino G, Vento G, Freni J Int J Mol Sci. 2024; 25(15).
PMID: 39126041 PMC: 11313383. DOI: 10.3390/ijms25158470.
Safak O, Wang S, Reyes C, Gurcinar I, Tokalov S, Cevik N Cancer Commun (Lond). 2023; 44(1):178-182.
PMID: 37877813 PMC: 10794007. DOI: 10.1002/cac2.12496.
Abascal J, Oh M, Liclican E, Dubinett S, Salehi-Rad R, Liu B Cells. 2023; 12(19).
PMID: 37830618 PMC: 10571973. DOI: 10.3390/cells12192404.
Sun S, Angell C, Savardekar H, Sundi D, Abood D, Benner B Cancer Immunol Immunother. 2023; 72(11):3461-3474.
PMID: 37528320 PMC: 10592087. DOI: 10.1007/s00262-023-03497-1.